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Abstract
Two once-daily inhaled bronchodilators, indacaterol and tiotropium, are widely used as first-
line therapy in stable COPD patients. This study was performed to compare the clinical effi-
cacy and safety between indacaterol and tiotropium in patients with moderate-to-severe
COPD. MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were
searched to identify all published randomized controlled trials (RCTs). The primary outcome
was trough forced expiratory volume in 1 second (FEV1) at week 12. Four RCTs were eligi-
ble for inclusion (three RCTs with moderate-to-severe COPD patients and one RCT with
only severe COPD patients). Trough FEV1 at weeks 12 and 26 were not significantly differ-
ent between indacaterol and tiotropium by the standardized mean difference with 0.014
(95% CI, -0.036, 0.063, I2= 23.5%) and with 0.037 (95% CI, -0.059 to 0.133, I2= 0%) along
with differences in means of 0.003L and 0.014L, respectively. Indacaterol and tiotropium
also showed similar St. George`s Respiratory Questionnaire (SGRQ) total scores and per-
centages of patients with SGRQ improvement ( 4 units) at week 26. The incidences of
nasopharyngitis, serious cardiovascular events, and serious adverse events were not differ-
ent between indacaterol and tiotropium, while those of cough (OR = 1.68, P< 0.001, and
PLOSONE | DOI:10.1371/journal.pone.0119948 March 23, 2015 1 / 12
OPEN ACCESS
Citation: Kim JS, Park J, Lim SY, Oh Y-M, Yoo KH,
Park YB, et al. (2015) Comparison of Clinical Efficacy
and Safety between Indacaterol and Tiotropium in
COPD: Meta-Analysis of Randomized Controlled
Trials. PLoS ONE 10(3): e0119948. doi:10.1371/
journal.pone.0119948
Academic Editor: Sanjoy Bhattacharya, Bascom
Palmer Eye Institute, University of Miami School of
Medicine, UNITED STATES
Received: October 31, 2014
Accepted: January 17, 2015
Published: March 23, 2015
Copyright: © 2015 Kim et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: The authors have no support or funding to
report.
Competing Interests: Min-Ji Kim is employed by
'Samsung Biomedical Research Institute' and Jung
Soo Kim, K. C. Carriere, and Hye Yun Park are
employed by 'Samsung Medical Center'. This do not
alter the authors' adherence to PLOS ONE policies
on sharing data and materials.
RR = 1.63) and COPD worsening (OR = 1.18, P = 0.003, and RR = 1.12) were higher for
indacaterol than tiotropium. However, when one study with only severe COPD patients was
removed from the meta-analysis, the difference in the incidence of COPD worsening be-
tween indacaterol and tiotropium became non-significant (OR = 1.13, P = 0.204, and RR =
1.09). The clinical efficacy and serious adverse events between indacaterol and tiotropium
were equivocal in patients with moderate-to-severe COPD. Cough is a common complaint
associated with indacaterol, and COPD worsening needs to be carefully monitored in se-
vere COPD patients when treated with indacaterol.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major global health burden with an esti-
mated prevalence of 300–600 million adults [1], and almost three million deaths annually
[2, 3]. It is characterized by progressive and irreversible airflow limitation, which adversely af-
fect respiratory symptoms, exercise tolerance, and quality of life [4]. Bronchodilators play a key
role in palliation of symptoms in patients with COPD, and long-acting bronchodilators are
currently recommended as maintenance bronchodilator therapy [4]. In particular, once-daily
inhaled bronchodilators provide 24-h therapeutic action, which leads to improved adherence
and efficacy compared with short-acting or twice-daily inhaled bronchodilators [5–8].
Various once-daily inhaled bronchodilators have been introduced. Among them, once-
daily anticholinergic tiotropium and once-daily β2-agonist indacaterol have been widely used
as maintenance treatment in cases of stable COPD. Both tiotropium and indacaterol have
shown significant clinical benefits in terms of improving lung function, symptoms, and quali-
ty of life over placebo, and they have no more safety concerns than the placebo have in stable
patients with moderate to severe COPD [9–12]. The concurrent use of an inhaled long-acting
β2-agonist (LABA) and inhaled long-acting muscarinic antagonist (LAMA) provides superior
efficacy with no increase in clinically relevant adverse events compared with individual agents
[13], but current guidelines recommend the combined use of LABA and LAMA when symp-
toms are not improved by a single agent [4]. Thus, single-agent therapy with LABA or LAMA
remains the initial treatment of choice in symptomatic COPD patients [4]. As there is lack of
evidence for recommending one class of long-acting bronchodilators over another for initial
treatment, the present study was performed to systematically compare current reports on the
clinical efficacy and safety of indacaterol versus tiotropium in stable patients with moderate to
severe COPD.
Methods
Literature search
We identified published studies fromMEDLINE, EMBASE, and the Cochrane Central Register
of Controlled Trials (to July 1, 2014) databases using keywords related to COPD, indacaterol
and RCTs (see S1 Table for details). The search filters provided by SIGN (http://www.sign.ac.
uk/methodology/filters.html) were used. The search was without language restriction and in-
cluded unpublished studies. Trials published solely in abstract form were excluded because the
methods and results could not be fully analyzed.
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Selection criteria
To meet our specific inclusion criteria, each study was required to satisfy the followings: (1) pa-
tients with stable moderate to severe COPD according to Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) diagnostic criteria [4]; (2) randomized control trials (RCTs)
with comparison of inhaled indacaterol vs. tiotropium; (3) at least 12 weeks of follow-up; (4)
report outcome of trough forced expiratory volume in 1 second (FEV1) at week 12; (5) written
in English.
Data extraction and risk of bias assessment
The title and abstract were independently analyzed by three authors (H.Y.P, J.Y.J, and J.S.K)
for screening. They independently assessed all studies for inclusion based on the criteria for
study design, outcome and intervention for participants. After they obtained full texts that
could be potential candidates, they assessed and confirmed eligibility for the analysis. Disagree-
ments were discussed and resolved by consensus. The two reviewers assessed the risk of bias of
included studies for sequence generation, allocation concealment, blinding of participants and
researchers, blinding of outcome assessment, incomplete outcome data addressed, and free of
selective reporting as recommended in the Cochrane Handbook of Systematic Reviews 5.1.
[14]. The authors compared their evaluations and reassessed the studies together as necessary.
Disagreement was solved by discussion and consensus between the authors.
Primary and secondary outcome analysis
The primary outcome was comparison of trough (24-h postdose) FEV1 of indacaterol with tio-
tropium at week 12 following treatment. Secondary outcomes consisted of comparison of
trough FEV1, St. George`s Respiratory Questionnaire (SGRQ) total score and the minimal clin-
ically important difference (MCID) of SGRQ total score at week 26. Based on empirical data
and interviews with patients, a mean change score of 4 units was associated with slightly effica-
cious treatment, which is referred to as MCID [15].
We also assessed detailed adverse events, including the incidence of any adverse events,
nasopharyngitis, cough, COPD worsening, serious adverse events, and serious cardiovascular
events (cardiac failure and myocardial ischemic disease).
Statistical analysis
We used Comprehensive Meta-Analysis, Version 2 (Englewood, NJ, USA; Biostat, Inc.), to
carry out meta-analysis of the included studies. Outcomes were pooled using standardized dif-
ferences in means (SMD) under the fixed effects model or odds ratio (OR). We also added dif-
ference in means (MD) and relative ratios (RR) whenever possible. The precision of the
estimates was quantified by the 95% confidence interval (CI). Heterogeneity was measured by
the Higgins and Green I2 test, which is calculated as 100%×(Q–df)/Q, where Q is the observed
chi-squared statistic and the degrees of freedom (df) is the number of studies less one [14]. The
I2 ranges between 0% (no heterogeneity) and 100% (maximal heterogeneity), and heterogeneity
was considered to be substantial at P< 0.10 and I2> 50% [14]. Heterogeneity was explored
with sensitivity analysis. We also conducted the potential publication bias with Egger’s regres-
sion test and the funnel-plot based Trim and Fill method [16]. P values< 0.05 (two-tailed test)
was considered significant. The methodological quality of the selected trials was assessed using
the criteria described in the Cochrane Handbook [17].
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PLOSONE | DOI:10.1371/journal.pone.0119948 March 23, 2015 3 / 12
Results
Fig. 1 shows how relevant studies were identified. A total of 1,537 articles were found by
searching databases. We excluded 517 duplicated articles and an additional 844 articles based
on our inclusion criteria. One hundred seventy two trials were excluded as 168 trials was absent
of either indacaterol or tiotropium and four did not provide details of trough FEV1 at week 12.
Thus, four randomized controlled studies finally met the inclusion criteria [18–21]. A total of
6,819 subjects were enrolled with 3,407 in the indacaterol 150 μg group and 3,412 subjects in
the tiotropium 18 μg group. The mean age of patients was 63.7 years, and 73% were male.
Three studies (INHANCE, INTENSITY, and SHINE) had entry criteria for symptomatic pa-
tients with moderate to severe COPD [18–20], while one study (INVIGORATE) included only
severe COPD patients [21]. Three studies (INHANCE, INTENSITY, and INVIGORATE)
Fig 1. Flowchart for identification of studies used. RCT = randomized controlled trial.
doi:10.1371/journal.pone.0119948.g001
Indacaterol and Tiotropium
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compared clinical outcomes between indacaterol 150 μg and tiotropium 18 μg. In the one re-
maining study (SHINE), patients received QVA149 (indacaterol/glycopyrronium 110/50 μg),
indacaterol 150 μg, glycopyrronium 50 μg, open label tiotropium 18 μg, or placebo to investi-
gate efficacy and safety. The duration of follow-up ranged from 12 weeks to 52 weeks. Table 1
presents a summary of the general characteristics of the four RCTs [18–21].
Risk of bias in the included studies
The assessments performed by the authors of each risk of bias item for each included RCT are
summarized in Table 2. A high risk of bias for blinding of participants was reported in two
studies due to open labeled study.
Table 1. Characteristics of included studies.
Study Treatment
duration
(weeks)
COPD
criteria
(GOLD)
Number of
subjects
Men,
%
Age
(mean)
Drug and
Dose
Baseline FEV1 L
(% Predicted)
Primary
outcome
Donohue et al 2010 [18]
(INHANCE study)
26 Moderate to
Severe
416 62 63.4 Indacaterol
150μg
1.52 (56.1) Trough FEV1
at week 12
415 65 64.0 Tiotropium
18μg
1.45 (53.9)
Buhl et al 2011 [19]
(INTENSITY study)
12 Moderate to
Severe
794 70 63.6 Indacaterol
150μg
1.53 (54.6) Trough FEV1
at week 12
799 67 63.4 Tiotropium
18μg
1.52 (54.3)
Bateman et al 2013 [20]
(SHINE study)
26 Moderate to
Severe
476 74 63.6 Indacaterol
150μg
1.5 (54.9) Trough FEV1
at week 26
480 75 63.5 Tiotropium
18μg
1.5 (55.1)
Decramer et al 2013 [21]
(INVIGORATE study)
52 Severe 1721 78 64.0 Indacaterol
150μg
1.13 (40.2) Trough FEV1
at week 12
1718 76 64.0 Tiotropium
18μg
1.14 (40.7)
COPD = Chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 second; GOLD = Global Initiative for Chronic Obstructive Lung
Disease.
doi:10.1371/journal.pone.0119948.t001
Table 2. Risk of bias amongst included studies.
Source Sequence
generation
Allocation
concealment
Blinding of
participants and
researchers
Blinding of
outcome
assessment
Incomplete
outcome data
addressed
Free of
selective
reporting
Donohue et al 2010 [18]
(INHANCE study)
Unclear Low risk High risk Low risk High risk Low risk
Buhl et al 2011 [19]
(INTENSITY study)
Unclear Low risk Low risk Low risk Low risk Low risk
Bateman et al 2013 [20]
(SHINE study)
Unclear Unclear High risk Low risk Low risk Low risk
Decramer et al 2013 [21]
(INVIGORATE study)
Low risk Low risk Low risk Low risk Low risk Low risk
COPD = Chronic obstructive pulmonary disease; OR = Odds ratio.
doi:10.1371/journal.pone.0119948.t002
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Primary outcome
As shown in Fig. 2, the analysis of four studies comparing indacaterol with tiotropium showed
no significant differences in trough FEV1 at week 12 (MD = 0.003L and SMD = 0.014, 95% CI,
-0.036 to 0.063, P = 0.587). There was little evidence of statistical heterogeneity (Higgins and
Green I2 = 23.5%, P = 0.270, Q = 3.92 for 3 df). When the study of patients with only severe
COPD (INVIGORATE) [21] was removed, the heterogeneity among studies dropped to 0%,
but trough FEV1 at week 12 was not significantly different between indacaterol and tiotropium
(P = 0.098).
Secondary outcome
Trough FEV1 at week 26 of indacaterol and tiotropium was reported in two studies
(INHANCE and SHINE) [18, 20]. There were 825 subjects in the indacaterol 150 μg group and
836 subjects in the tiotropium 18 μg group. The MD of trough FEV1 at week 26 between the
two groups was 0.014L and the SMD was 0.037, which was not statistically significant (95% CI,
-0.059 to 0.133, P = 0.454). There was no evidence of statistical heterogeneity (Q = 0.07 for 1
df, I2 = 0%, P = 0.787) (Fig. 3). The test for asymmetry was not assessed because only two RCTs
were analyzed.
The SGRQ total score at week 26 was reported in three studies (INHANCE, SHINE and IN-
VIGORATE) [18, 20, 21]. As shown in Fig. 4A, the MD was—0.374 and the SMD was-0.013
between indacaterol and tiotropium, which was not significant (95% CI, -0.072 to 0.045,
P = 0.657) and there was little evidence of heterogeneity (Q = 3.96 for 2 df, I2 = 49.5%,
P = 0.138). When the INVIGORATE study [21] was removed from the analysis, the
Fig 2. Indacaterol versus Tiotropium on trough FEV1 at week 12. FEV1 = forced expiratory volume in 1 second; df = degrees of freedom.
doi:10.1371/journal.pone.0119948.g002
Indacaterol and Tiotropium
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heterogeneity among studies dropped dramatically (0%), but SGRQ total score at week 26 of
indacaterol was not significantly different with that of tiotropium (P = 0.092).
Three studies (INHANCE, SHINE and INVIGORATE) presented the decreased SGRQ
total score by at least 4 units (MCID) at week 26 [18, 20, 21]. The percentage of patients with
MCID in the SGRQ total score was not different between two groups (pooled OR = 1.07, 95%
CI, 0.95 to 1.21, P = 0.267). The heterogeneity among three studies was substantial by the Hig-
gins and Green test (Q = 11.13 for 2 df, I2 = 82.0%, P = 0.004). Without INVIGORATE study,
the heterogeneity became 0% and the percentage of patients with MCID in the SGRQ at week
26 was significantly higher in those using indacaterol than in those receiving tiotropium
(pooled OR = 1.40, 95% CI, 1.15 to 1.71, P = 0.001) (Fig. 4B).
Adverse events
As shown in Table 3, the incidence of any adverse events was significantly higher in patients
treated with indacaterol than in those treated with tiotropium (58.8% vs. 56.2%, pooled
OR = 1.12; 95% CI, 1.01 to 1.23, P = 0.028, and RR = 1.04). With regard to adverse events, the
incidence of nasopharyngitis was similar between the two once-daily inhaled bronchodilators,
while patients using indacaterol experienced cough (6.3% vs. 3.8%, pooled OR = 1.68; 95%
CI = 1.34–2.10, P< 0.001, and RR = 1.63) and COPD worsening (31.1% vs. 27.8%, pooled
OR = 1.18; 95% CI = 1.06–1.32, P = 0.003, and RR = 1.12) at higher rates compared to those
using tiotropium. When three studies (INHANCE, INTENSITY, and SHINE) [18–20] were
used in the meta-analysis, the incidence rates of any adverse events (52.4% vs. 50.2%, pooled
OR = 1.09; 95% CI = 0.95–1.26, P = 0.206, and RR = 1.04) and COPD worsening (18.4% vs.
16.8%, pooled OR = 1.13; 95% CI = 0.94–1.35, P = 0.204, and RR = 1.09) were not significantly
different between the two once-daily inhaled bronchodilators. However, the incidence of
cough was still higher in patients receiving indacaterol than in those receiving tiotropium
(6.2% vs. 4.4% pooled OR = 1.45; 95% CI = 1.07–1.97, P = 0.018, and RR = 1.42). In both meta-
analyses, there were no significant differences in the rates of serious adverse events or serious
cardiovascular adverse events between the two once-daily inhaled bronchodilators.
Discussion
This meta-analysis showed that indacaterol (150 μg) was as effective as tiotropium (18 μg) in
improving trough FEV1 at weeks 12 and 26 among patients with moderate to severe stable
COPD. Our data were consistent with those in the meta-analysis reported by Rodrigo et al,
[22] which indicated similar efficacy between indacaterol and tiotropium in terms of trough
FEV1 in moderate to severe COPD patients with the INHANCE and INTENSITY studies
[18, 19]. We extended these findings by adding two large RCTs, including the INVIGORATE
study conducted only with severe COPD patients [20, 21]. With respect to quality of life,
Fig 3. Indacaterol versus Tiotropium on trough FEV1 at week 26. FEV1 = forced expiratory volume in 1 second; df = degrees of freedom.
doi:10.1371/journal.pone.0119948.g003
Indacaterol and Tiotropium
PLOSONE | DOI:10.1371/journal.pone.0119948 March 23, 2015 7 / 12
SGRQ total score at week 26 was also similar between the two once-daily inhaled bronchodila-
tors in meta-analysis with INHANCE, SHINE, and INVIGORATE studies [18, 20, 21]. Most
importantly, the percentage of patients with MCID in the SGRQ at week 26 showed no differ-
ence between those using indacaterol and those using tiotropium, which had substantial het-
erogeneity in the meta-analysis. As shown in Table 1, one of the four RCTs (the
Fig 4. Indacaterol versus Tiotropium on SGRQ at week 26. (A) Pooled standardized difference in means
for SGRQ total score at week 26 with 95% CIs of eligible studies comparing indacaterol vs tiotropium. (B)
Pooled odds ratio for percentage of patients with MCID (decrease 4 units) of SGRQ total score at week 26
of eligible studies comparing indacaterol vs tiotropium. SGRQ = St. George`s Respiratory Questionnaire;
MCID = minimal clinically important difference; SGRQ = St. George`s Respiratory Questionnaire.
doi:10.1371/journal.pone.0119948.g004
Indacaterol and Tiotropium
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INVIGORATE study) targeted only severe COPD patients. To examine how sensitive our find-
ings are to the one study, we performed another analysis of efficacy, isolating the INVIGO-
RATE study [21]. Similar to the meta-analysis of Rodrigo et al, [22] the results indicated that
the percentage of patients with MCID in the SGRQ at week 26 was significantly higher among
patients receiving indacaterol than those receiving tiotropium with the absence of heterogene-
ity in meta-analysis of the INHANCE and SHINE studies [18, 20]. However, the result needs
to be interpreted with caution, because MCID differences were not derived on the basis of dif-
ferences between two once-daily inhaled bronchodilators; indacaterol (150 μg) and tiotropium
(18 μg).
In addition to efficacy, adverse events are key factors in choosing and maintaining a particu-
lar bronchodilator. The present meta-analysis indicated that patients receiving indacaterol had
significantly higher rates of any adverse event, COPD worsening, and cough compared to
those treated with tiotropium, while the rates of nasopharyngitis, serious cardiovascular ad-
verse events, such as cardiac failure and myocardial ischemic disease, and serious adverse
events did not differ between indacaterol and tiotropium. We conducted a meta-analysis of the
adverse events as well as efficacy using three RCT studies (INHANCE, INTENSITY, and
SHINE) with moderate and severe COPD patients and excluding the INVIGORATE study.
The results showed no statistically significant differences in rates of any adverse events or
COPD worsening between patients treated with indacaterol and those treated with tiotropium
[18–20]. In these three RCTs, the mean FEV1% predicted was 54–56%, indicating that more
than half of the population in each study ( 60% in INTENSITY and SHINE) consisted of
moderate COPD patients [19, 20]. On the other hand, only severe COPD patients were en-
rolled in the INVIGORATE study [21] and the number of subjects (n = 3439) was similar to
the total number of subjects in the other three RCTs (n = 3380). It suggests that disease severity
may explain these differences in adverse events and COPD worsening between meta-analyses.
Besides the severity of COPD and the number of participants, multiple other factors might
Table 3. Adverse events of Indacaterol vs. Tiotropiummonotherapy.
Outcome No. No. of studies Relative Risk Odds Ratio (95% CI) I2, % P Value
INHANCE, INTENSITY, SHINE and INVIGORATE studies [18–21]
Any adverse events 6,819 4 1.04 1.12 (1.01 to 1.23) 0 0.028
Nasopharyngitis 6,819 4 1.03 1.04 (0.85 to 1.26) 0 0.720
Cough 6,819 4 1.63 1.68 (1.34 to 2.10) 13.03 <0.001
COPD worsening 6,819 4 1.12 1.18 (1.06 to 1.32) 11.95 0.003
Serious adverse events 6,819 4 1.02 1.03 (0.87 to 1.21) 0 0.748
Serious cardiovascular adverse event*† 5,226 3 0.91 0.91 (0.58 to 1.41) 0 0.657
INHANCE, INTENSITY, and SHINE studies [18–20] ‡
Any adverse events 3,380 3 1.04 1.09 (0.95 to 1.26) 0 0.206
Nasopharyngitis 3,380 3 0.92 0.92 (0.70 to 1.21) 0 0.548
Cough 3,380 3 1.42 1.45 (1.07 to 1.97) 0 0.018
COPD worsening 3,380 3 1.09 1.13 (0.94 to 1.35) 32.84 0.204
Serious adverse events 3,380 3 1.01 1.00 (0.73 to 1.38) 17.35 0.982
Serious cardiovascular adverse event*† 1,787 2 1.01 1.01 (0.54 to 1.88) 0 0.989
COPD = Chronic obstructive pulmonary disease.
*INTENSITY study was not included in the analysis of serious cardiovascular event.
†Serous cardiovascular events of INHANCE study were analyzed with both indacaterol 150ug and 300ug group.
‡INVIGORATE study with only severe COPD patients was excluded in subgroup analysis.
doi:10.1371/journal.pone.0119948.t003
Indacaterol and Tiotropium
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have influenced these different results. Given that COPD exacerbations were included in
COPD worsening, the durations of the three RCTs (INHANCE, INTENSITY, and SHINE)
[18–20] were relatively short (12–26 weeks) to evaluate COPD worsening compared to the
INVIGORATE study (52 weeks) [21].
Regardless of whether we performed the analysis with three RCTs (INHANCE, INTENSI-
TY, and SHINE) [18–20] or four RCTs (with addition of the INVIGORATE study) [18–21],
patients who received indacaterol showed a higher rate of cough than those treated with tiotro-
pium. Cough is the most commonly reported adverse effect associated with the use of indaca-
terol. Indacaterol was initially developed as the maleate salt, which was associated with a cough
occurring post-inhalation according to the manufacturer’s report. The post-inhalation cough
occurred within 15 s after inhalation and lasted for around 6 s, and was not associated with
post-inhalation bronchospasm or any negative effects on safety or efficacy [23].
The review was performed according to the methodological criteria suggested by scientific
guidelines [24]. Inclusion criteria were clearly defined and the risk of bias was formally as-
sessed. As with all meta-analyses, there is a potential bias in analyzing published studies, which
are more likely to have positive results. We investigated this possibility using Egger`s regression
test for asymmetry, and the funnel-plot based Trim and Fill method. The Egger’s regression
test suggested a significant asymmetry, but the Trim and Fill adjusted test did not reverse the
fixed effects model result, confirming that there was no significant difference in the primary
outcome. However, as we analyzed only four studies, statistical power was expected to be low
[16, 17].
In summary, this study suggests that clinical effects on lung function and quality of life were
not different between the two once-daily inhaled bronchodilators; indacaterol (150 μg) and tio-
tropium (18 μg), with acceptable safety profiles. Cough was the most common adverse effect
associated with indacaterol, and COPD worsening occurred more frequently in patients treated
with indacaterol than in those treated with tiotropium, particularly among patients with severe
COPD.
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